News Image

Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer

Provided By GlobeNewswire

Last update: Jan 12, 2025

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, and Orano Med, a clinical-stage radiopharmaceutical company and a pioneer in the development of targeted alpha-particle therapies (TAT) with 212Pb (lead-212), today announced the expansion of their strategic collaboration.

Read more at globenewswire.com

MOLECULAR PARTNERS AG -ADR

NASDAQ:MOLN (7/25/2025, 8:07:47 PM)

After market: 3.6 -0.27 (-6.94%)

3.8685

-0.13 (-3.29%)



Find more stocks in the Stock Screener

Follow ChartMill for more